1. Home
  2. MIRM vs RVLV Comparison

MIRM vs RVLV Comparison

Compare MIRM & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • RVLV
  • Stock Information
  • Founded
  • MIRM 2018
  • RVLV 2003
  • Country
  • MIRM United States
  • RVLV United States
  • Employees
  • MIRM N/A
  • RVLV N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • RVLV Catalog/Specialty Distribution
  • Sector
  • MIRM Health Care
  • RVLV Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • RVLV Nasdaq
  • Market Cap
  • MIRM 2.5B
  • RVLV 1.4B
  • IPO Year
  • MIRM 2019
  • RVLV 2019
  • Fundamental
  • Price
  • MIRM $51.38
  • RVLV $20.83
  • Analyst Decision
  • MIRM Strong Buy
  • RVLV Buy
  • Analyst Count
  • MIRM 9
  • RVLV 15
  • Target Price
  • MIRM $66.22
  • RVLV $26.20
  • AVG Volume (30 Days)
  • MIRM 477.5K
  • RVLV 1.2M
  • Earning Date
  • MIRM 08-06-2025
  • RVLV 08-05-2025
  • Dividend Yield
  • MIRM N/A
  • RVLV N/A
  • EPS Growth
  • MIRM N/A
  • RVLV 106.68
  • EPS
  • MIRM N/A
  • RVLV 0.71
  • Revenue
  • MIRM $379,251,000.00
  • RVLV $1,156,039,000.00
  • Revenue This Year
  • MIRM $35.83
  • RVLV $7.71
  • Revenue Next Year
  • MIRM $16.83
  • RVLV $7.64
  • P/E Ratio
  • MIRM N/A
  • RVLV $29.33
  • Revenue Growth
  • MIRM 69.31
  • RVLV 9.09
  • 52 Week Low
  • MIRM $34.47
  • RVLV $14.88
  • 52 Week High
  • MIRM $54.23
  • RVLV $39.58
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 63.09
  • RVLV 50.68
  • Support Level
  • MIRM $49.22
  • RVLV $20.12
  • Resistance Level
  • MIRM $51.93
  • RVLV $21.93
  • Average True Range (ATR)
  • MIRM 1.40
  • RVLV 0.83
  • MACD
  • MIRM -0.15
  • RVLV -0.00
  • Stochastic Oscillator
  • MIRM 86.39
  • RVLV 52.79

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Share on Social Networks: